Crispr Therapeutics AG reports results on Monday 9 November. Revenue over the twelve months to Q3 2026 was $25.2 million, which fell 34.3% on the year before, yet the rate of decline improved by 30.5 percentage points over the prior quarter. The report will test whether that deceleration is enough to matter against losses the company is still booking at scale.
Source: reported quarterly EPS and aggregated third-party estimates. Historical surprises are context, not a forecast.
View chart data
| Period | Reported EPS | Analysts' estimate |
|---|---|---|
| Dec '25 | −$1.37 | −$1.23 |
| Mar '26 | −$1.28 | −$1.23 |
| Jun '26 | −$0.94 | −$1.18 |
| Sep '26 | −$1.15 | −$1.06 |
What analysts expect from Crispr Therapeutics AG
The analysts' average EPS estimate for the quarter is −$1.16, in a range from −$2.02 to −$0.51. The average revenue estimate is $17.4 million. For the full year, the analysts' average EPS estimate is −$4.45, which would be up 31.3% on last year based on 19 analysts. Of the recommendations on file, 13 are positive, 10 neutral and 0 negative.
Earnings surprise model
The model estimates EPS could land below the analysts' average estimate by 3.0%. Its estimated chance of an EPS beat is 37.5%, based on the last 4 quarters. The model shrinks the median recent surprise toward zero and uses a neutral prior for beat frequency; this small sample is a reference estimate, not company guidance.
Crispr Therapeutics AG's record against estimates
The company reported EPS above the analysts' average estimate in 1 of the last 4 quarters. Last quarter, EPS of −$1.15 compared with an estimate of −$1.06, below it by 8.5%.
The decline in sales is easing
The revenue decline is slowing: the growth rate was up 30.5 percentage points on the rate a quarter earlier. The margins move the other way. The trailing operating margin was negative, at −2114.8%, down 616.5 percentage points from a year earlier, and the trailing net margin was negative, at −1812.1%. The company made a net loss of $456.1 million over the twelve months.
The cash burn is almost entirely an operating outflow. Operating cash flow over the twelve months was −$374.6 million, while capital spending was $2.1 million, or 8.3% of revenue. Free cash flow, operating cash flow less capital spending, was −$376.7 million. The free-cash-flow margin was −1496.6% of revenue, down 705.8 percentage points from a year earlier. The average diluted share count rose 10.0% over the year.
Set against its own history, the current readings are better than most of the past. Today's free-cash-flow margin of −1496.6% is higher than 28% of the company's own past quarterly readings, which have ranged from −44484.9% to 972.3%. Today's operating margin of −2114.8% is higher than 28% of past readings, which have ranged from −56190.4% to 49.7%. Today's twelve-month revenue growth rate of −34.3% is higher than 47% of past readings, which have ranged from −99.9% to 127154.9%.
Questions this report will answer
The report will answer whether the pick-up in revenue growth continues, whether results land above or below the analysts' expectations set out above, and whether margins hold at the trailing levels above.
